Characteristics and Treatment Outcomes of 
*Propionibacterium acnes* Prosthetic Shoulder Infections in Adults

Damani A. Piggott,†4 Yvonne M. Higgins,† Michael T. Melia,† Brandon Ellis,† Karen C. Carroll,†2 Edward G. McFarland,‡ and Paul G. Auwaerter†6

†Division of Infectious Diseases, ‡Division of Medical Microbiology, Department of Pathology, §Division of Shoulder Surgery, Department of Orthopedic Surgery, Johns Hopkins University School of Medicine, and 6Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases, Baltimore, Maryland

**Background.** Prosthetic joint infections (PJIs) significantly complicate joint arthroplasties. *Propionibacterium acnes* is an increasingly recognized PJI pathogen, yet limited clinical and therapeutic data exist. We sought to examine characteristics of *P. acnes* shoulder PJsIs and compare surgical and nonsurgical management outcomes.

**Methods.** A retrospective analysis of *P. acnes* shoulder PJsIs was conducted at an academic center in Baltimore, Maryland from 2000 to 2013.

**Results.** Of 24 cases of *P. acnes* shoulder PJsIs, 92% were diagnosed after extended culture implementation; 42% in the delayed and 46% in the late postsurgical period. Joint pain and diminished function were the predominant presenting clinical signs. Erythrocyte sedimentation rate and C-reactive protein elevations occurred in 47% and 44%, respectively. All tested isolates were susceptible to β-lactams, moxifloxacin, vancomycin, and rifampin. Clindamycin resistance was identified in 6%. Of the antibiotic-only treated cases, 67% had a favorable clinical outcome compared with 71% (*P* = 1.0) of cases with a combined antibiotic-surgical approach. Favorable outcome with and without rifampin therapy was 73% and 60% (*P* = .61), respectively.

**Conclusions.** *Propionibacterium acnes* PJI diagnoses increased with extended culture. Inflammatory markers were elevated in a minority of cases. Isolates maintained broad antimicrobial susceptibility. Compared to combined antibiotic-surgical approaches, antibiotic-only approaches were similarly successful in selected cases.

**Keywords.** antimicrobial susceptibility; *Propionibacterium acnes*; prosthetic joint infection; shoulder prosthesis.

Over 1 million prosthetic joints are placed in the United States each year. With an aging population, this number is projected to increase 4-fold over the next 2 decades [1–3]. A notable proportion of these joints subsequently fail. Prosthetic joint infections (PJIs) have been considered to be the most serious cause of subsequent joint failure, occurring in up to an estimated 2% of arthroplasties [1, 4–6]. In addition to the clinical impact, the economic burden of PJIs is markedly high, with an estimated cost in the United States approaching 1 billion dollars annually [5, 7].

*Propionibacterium acnes* is a Gram-positive anaerobic bacillus. It is a human commensal organism, primarily found in skin and superficial mucosal sites, with a predilection for pilosebaceous follicles that exist in the upper body such as the shoulder region [8–10]. Initially considered an important agent in the pathogenesis of acne vulgaris, *P. acnes* has been more recently implicated in serious deep-seated postoperative and medical device-related infections, particularly PJIs [11–13]. With improved diagnostics, including extended culture protocols, *P. acnes* has been specifically recognized as a dominant organism in infections involving shoulder prostheses [14–23]. Yet, there has been a paucity of data on the clinical and microbiologic characteristics of such infections.

Treatment of PJIs beyond the acute postoperative period has traditionally relied on an appropriate antimicrobial regimen, combined with a surgical approach dependent on stability of the prosthesis, state of the periprosthetic tissue, patient comorbidity, and characteristics of the infecting organism [1, 3, 6]. Surgical options include debridement with implant retention or antibiotic spacer implantation with no subsequent arthroplasty, a 1-stage revision with immediate reimplantation of a new prosthesis, a 2-stage revision with reimplantation several months after prosthesis removal, permanent prosthesis removal, and amputation. Medical management options have been manifold, largely because antimicrobial activity against *P. acnes* has been reported for a wide spectrum of agents [24]. However, with the increasing use of antimicrobial agents for acne vulgaris, advancing resistance of *P. acnes* isolates has been reported, particularly...
in refractory cases of acne [25–27]. The susceptibility patterns of 
*P. acnes* isolates implicated in deep-seated infections have been 
less well characterized.

Medical management of PJIs without surgical intervention 
has been considered to result in poorer clinical outcomes [1, 
28]. Such a limited approach has typically been reserved for pa-

tients with inoperable status [1, 6]. Occasionally, this strategy 
has been considered in clinical practice for low virulence organ-

isms, although with limited supporting data. *Propionibacterium 
acnes* has been considered a low virulence organism, but little 
data exists on the comparative advantage of combined medical 
and surgical management to that of medical management alone 
for infections involving this organism.

We performed a retrospective analysis to describe clinical and 
laboratory characteristics of *P. acnes* prosthesis shoulder joint 
infected and antimicrobial susceptibility patterns of the asso-

ciated isolates over a 14-year period. We further describe short-
term treatment outcomes for surgical and alternative medical 
approaches to the management of these infections.

**PATIENTS AND METHODS**

**Hospital Setting and Study Population**

This study was conducted at the Johns Hopkins Hospital and 
Clinics in Baltimore, Maryland. Linkage to the Johns Hopkins 
Hospital microbiology database system was used to identify 
cases from January 2000 through December 2013. Patients 
age 18 years and older with a positive *P. acnes* culture from 
the shoulder joint with a prior shoulder prosthesis were identi-

cied for study inclusion. This study was approved by the Johns 
Hopkins Institutional Review Board.

**Specimen Collection and Microbiologic Assessment**

Joint fluid aspirates and operative tissue specimens were collect-
ed using standard protocols and transported to the Microbiol-

ogy Laboratory for processing. Joint fluid aspirates were 
transported in BD BBL Port-A-Cul vials (Becton, Dickinson 
and Company, Sparks, MD), and tissue specimens were placed 
in a sterile container and transported to the Microbiology Lab-

oratory within 1 hour of collection. Specimens were then pro-

cessed and inoculated onto standard agars, including Brucella 
-blood agar (Anaerobe Systems, Morgan Hill, CA), and BD 

BBL Chopped Meat Broth (Becton, Dickinson and Company). 
Aerobic plates and chopped meat broths were incubated in 5% 
CO₂ at 35°C. Anaerobic plates and broth subcultures were incu-
bated in an AS-580 anaerobe chamber (Anaerobe Systems) at 
35°C. Aerobic blood and chocolate agar plates, as well as anaer-
obic Brucella and Phenyl-Ethyl-Alcohol agar plates, were held 
for 14 days. Chopped meat broths were subcultured both aer-
obically and anaerobically when turbid or terminally subcultured 
at day 10 if clear. Organism identification was obtained using 
the Bruker Microflex LT MALDI-TOF mass spectrometry sys-
tem (Bruker Daltonics, Billerica, MA), as well as Gram stain, 

**Definition**

A PJI was defined based on previously detailed criteria [1, 3, 22, 
29, 30]. A case was considered definite (1) if 2 or more culture 

specimens were positive for *P. acnes* with no other organisms on 
culture or (2) if 1 culture specimen was positive for *P. acnes* with 
no other organisms on culture and there was evidence of either 
joint purulence, histopathologic inflammation, or a sinus tract 
communicating with the prosthesis. A case was considered 
probable if 1 culture specimen was found to be positive for *P. 
acnes* and 1 of the following concomitant symptoms was pre-

sent: fever, constitutional symptoms (chills, fatigue, night 
sweats, weight loss, and anorexia), joint pain, joint swelling, 
joint warmth, wound drainage, or loss of range of motion. 
Cases were excluded if there was an alternative explanation 
for these symptoms (such as gout or rheumatoid arthritis re-
sponsive to therapy). There were no coexisting pathogens isolat-
ed in any of the cases included in this study.

**Data Collection**

Medical chart abstraction was performed using a standardized 

case report form to retrieve demographic, clinical, and laboratory 
data. Demographic data included age, sex, and race. Laboratory 
data included erythrocyte sedimentation rate (ESR), C-reactive 
protein (CRP), white blood cell (WBC) count, and percentage 
of neutrophils in the blood and synovial fluid. Imaging findings 
from plain films and computerized tomography scans were re-
corded. Laboratory and radiologic data recorded at diagnosis re-

fect findings before any surgical PJI treatment. The time from 
index surgery to diagnosis was recorded as the time from the 
last surgical procedure performed prediagnosis to the first pos-
tive *P. acnes* culture. Episodes were classified as early (<3 
months after surgery), delayed (3–24 months), or late (>24 
months) as previously described [6]. Time to culture positivity 
was recorded as the time from joint specimen attainment to 
positive culture growth.

**Antimicrobial Susceptibility Patterns**

The susceptibilities of *P. acnes* isolates were tested against a 
range of standard antimicrobial agents. Isolates were classified 
as susceptible as per the minimum inhibitory concentration 
(MIC) breakpoints set by the Clinical and Laboratory Standards 
Institute (CLSI): penicillin (≤0.5 µg/mL), piperacillin/tazo-

bac-tam (≤32/4 µg/mL), ertapenem (≤4 µg/mL), clindamycin 
(≤2 µg/mL), moxifloxacin (≤2 µg/mL), and metronidazole 
(≤8 µg/mL) or by the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST): vancomycin (<2 µg/mL) and 
rifampin (≤0.5 µg/mL) [11]. No CLSI or EUCAST break-

points were available for minocycline. The absolute MICs for 
isolates against minocycline are thus reported. Susceptibility
testing for penicillin was initiated in 2001; susceptibility testing for clindamycin, moxifloxacin, and vancomycin was initiated in 2009; susceptibility testing for piperacillin/tazobactam, ertapenem, and metronidazole was initiated in 2010; and susceptibility testing for rifampin was initiated in 2012.

**Follow-Up and Treatment Outcomes**

Antimicrobial therapeutic regimens and treatment outcomes were assessed through the last recorded clinical visit. Decisions on therapeutic regimens were based on the clinical judgment of the infectious disease and surgical specialist providers. The type, delivery method, and duration of antimicrobial therapy were recorded. In all cases, susceptibility profiles informed drug choice. Concomitant use of rifampin was also per the clinical judgment of the infectious disease physician with consideration of patient tolerability. Chart abstraction did not allow for precise determination of duration of intravenous (IV) versus oral therapy. However, of those who received IV antimicrobial therapy, the majority of patients received at least a 4- to 6-week course of IV therapy prior to transition to an oral regimen. The final clinical outcome was determined as per the clinical status at the last recorded clinical visit. An outcome was defined as favorable if there was a recorded improvement in pain symptoms and functional performance relative to a patient’s preintervention clinical status, without requirement for unplanned additional surgical debridement for putative persistent infection. Statistical analysis was performed using Fisher’s exact test and the Wilcoxon rank-sum test. A P value of <.05 was considered to be statistically significant.

**RESULTS**

There were 24 cases of *P. acnes* prosthetic shoulder joint infections identified over the 14-year period of this study. Of these, 11 (46%) met criteria for definite infection and 13 (54%) met criteria for probable infection. Right and left shoulder sites were similarly affected (54% and 46%, respectively). The demographic and clinical characteristics of these cases are reflected in Tables 1 and 4.

**Clinical and Laboratory Characteristics**

The median time from index surgery to diagnosis was 15.9 months (range, 0.4–251). The majority of diagnoses were delayed (42%) or late (46%), with only 3 cases (12%) diagnosed <3 months after surgery. All 24 cases presented with joint pain (Table 1). The majority of cases (88%) demonstrated impaired range of motion. Joint swelling (21%), joint warmth (8%), joint erythema (12%), and constitutional symptoms (8%) were uncommon. No fever or wound drainage was noted. There was no significant difference in clinical presentation by time to diagnosis (early vs delayed vs late) or by PJi type (definite vs probable infection). The proportion with an elevated ESR (>20 mm/hour) was 47% and elevated CRP (>0.5 mg/dL) was 44%. Peripheral WBC data, when obtained, was primarily in the normal range. The median synovial leukocyte count of aspirated joints was 2648 cells/mm³ (n = 13), with median synovial neutrophil percentage of 86% (n = 13). Of 15 cases undergoing operative intervention, intraoperative purulence was noted in 47% and tissue histopathologic inflammation in 67%.

**Radiologic Characteristics**

Abnormal radiologic findings were noted in a minority of cases. Radiolucency was observed in 20% of cases. Loosening of the prosthesis or subluxation was observed in 10% of cases, and fracture was observed in 5% of cases. No osteolysis was observed.

**Microbiologic Characteristics and Antimicrobial Susceptibility Patterns**

The majority of cases (92%) were identified after implementation of the extended culture protocol in 2009. The median time to culture positivity was 4.5 days (range, 3–14 days), which was unchanged in the extended culture period. However, 7 (29%) cases identified in the 2009–2013 period required a culture.
duration of >5 days for organism recovery. There was no significant difference in clinical presentation for cases with recovery at >5 days relative to those with earlier culture detection. All tested isolates were susceptible to β-lactams (penicillin, piperacillin/tazobactam, ertapenem), vancomycin, moxifloxacin, and rifampin (Table 2). As is typical of P. acnes, all were resistant to metronidazole. The rate of resistance to clindamycin was 6%. The MIC range for minocycline was 0.03–0.25 μg/mL.

Antimicrobial and Surgical Treatment
There were 21 patients (88%) who received antibiotic treatment and 15 (62%) who received surgical intervention. There were 7 patients (29%) who received antibiotic treatment only and 14 (58%) who received concomitant antibiotic and surgical treatment (Tables 3 and 4); 1 patient received surgical intervention without antibiotic therapy. Of the 15 surgical cases, 1 (7%) underwent debridement and retention, 4 (27%; 1 planned, 3 unplanned) underwent a 1-stage procedure, 7 (47%) underwent a 2-stage procedure, and 3 (20%) underwent prosthesis removal with spacer placement without reimplantation. All 3 prosthesis removals were per patient preference. The median duration of antibiotic administration was 6.3 months (range, 1.3–50.7); 7 months (range, 4.1–50.7) for those receiving antibiotic only and 5.5 months (range, 1.3–21.3) for those receiving both antibiotic and surgery. The majority of antibiotic regimens (67%) used a β-lactam (penicillin or amoxicillin). Other antimicrobial agents used included minocycline or doxycycline, vancomycin, and clindamycin. Rifampin was used in 15 (71%) cases. The median duration of rifampin therapy was 3.9 months (range, 0.3–17.8). Of the 7 cases receiving antibiotic therapy only, the rationale for the decision for no surgical intervention included the presence of metastatic rectal cancer (1), poor surgical risk secondary to multiple comorbidities (1), insurance limitations (1), stable prosthesis (1), limited pain (1), and patient preference (2).

Table 2. Microbial Susceptibility Patterns of Propionibacterium acnes Isolates

| Antimicrobial Agent                      | No. (%) |
|-----------------------------------------|---------|
| Penicillin                              | 19 (100)|
| Piperacillin/tazobactam                 | 7 (100) |
| Ertapenem                               | 7 (100) |
| Moxifloxacin                            | 10 (100)|
| Rifampin                                | 6 (100) |
| Vancomycin                              | 14 (100)|
| Clindamycin                             | 17 (94) |
| Metronidazole                           | 0 (0)   |
| Minocycline MIC 0.03–0.25 μg/mL<sup>a</sup> |         |

Abbreviations: CLSI, Clinical and Laboratory Standards Institute; EUCAST, European Committee on Antimicrobial Susceptibility Testing; MIC, minimum inhibitory concentration.

<sup>a</sup> Data are number (%) of cases, unless otherwise indicated; susceptibilities determined as per CLSI/EUCAST breakpoints.

<sup>b</sup> Range of MIC values for 11 tested isolates; no CLSI interpretive breakpoints are available for minocycline; tetracycline susceptible MIC breakpoint is ≤4 μg/mL.

Table 3. Treatment Outcomes for Propionibacterium acnes Shoulder Prosthetic Joint Infection

| Treatment                          | Total Treated No. (%) | Favorable Outcome<sup>a</sup> No. (%) |
|------------------------------------|-----------------------|---------------------------------------|
| Type of treatment<sup>b</sup>      |                       |                                       |
| Antibiotic therapy only            | 7 (29)<sup>c</sup>   | 4 (67)                                |
| Antibiotic therapy + surgery       | 14 (58)               | 10 (71)                               |
| Surgical type<sup>b</sup>          |                       |                                       |
| 1-stage exchange                   | 4 (27)<sup>c</sup>   | 3 (75)                                |
| 2-stage exchange                   | 7 (47)               | 6 (86)                                |
| Rifampin therapy<sup>a</sup>       |                       |                                       |
| Yes                                | 15 (71)<sup>d</sup>  | 11 (73)                               |
| No                                 | 5 (24)               | 3 (60)                                |

<sup>a</sup> Data are number (% of cases receiving antibiotic therapy).

<sup>b</sup> Data are number (% of surgical cases).

<sup>c</sup> Data are number (% of all cases).

<sup>d</sup> Data are number (% of cases receiving antibiotic therapy).

<sup>*</sup> P < .05.

Treatment Outcomes
The median follow-up duration was 24 months (range, 4.6–65.9). Antibiotic-only approaches were first initiated in mid-2009. Consequently, the median follow-up duration for those receiving antibiotic therapy only was 12.2 months (range, 4.6–51) compared with 27.8 months (range, 7.3–65.9) for those receiving both antibiotic therapy and surgery (P = .14). The proportion of cases with a favorable outcome was similar for those treated with antibiotic therapy and surgery (71%) compared with those treated with antibiotic therapy only (67%) (Table 3; P = 1.0). Outcomes were similar for those who underwent a 1-stage (75%) or 2-stage procedure (86%) (P = 1.0). A favorable outcome was noted for 73% of cases with rifampin therapy compared with 60% without rifampin therapy (P = .61). However, of the 15 cases in which rifampin was administered, this agent had to be discontinued in 6 (40%) due to adverse reactions ranging from gastrointestinal and influenza-like symptoms (resolved post cessation) to angioedema and severe rash including a case of acute generalized exanthematous pustulosis requiring hospitalization.

DISCUSSION
It has generally been considered that the optimal management of PJIs beyond the early period requires the combination of antimicrobial therapy with surgical intervention [1, 3, 6, 14, 23]. Antimicrobial therapy in the absence of surgical intervention has been considered to primarily result in unacceptably high rates of failed outcomes [1, 28]. However, few studies have examined the comparative management of P. acnes infections with nonsurgical approaches. In this 14-year series of 24 P. acnes prosthetic shoulder infections, we found treatment with a nonsurgical antibiotic-only approach to have an outcome comparable to that of a traditional combined medical-surgical approach. Our findings suggest that for P. acnes shoulder
| Case No. | Clinical Signs and Symptoms | Time to Culture Positivity– Days (No. of Positive Specimensa) | Time From Index Surgery–Months (Year of Diagnosis) | Laboratory Markers, Radiographic and Operative Findings | Treatment (Antibiotic Duration– Days) | Favorable Clinical Outcome |
|----------|-----------------------------|---------------------------------------------------------------|-----------------------------------------------------|------------------------------------------------------|--------------------------------------|---------------------------|
| 1        | Joint pain, ↓ROM            | 3 (3)                                                         | 1.9 (2001)                                          | ESR > 130, CRP 10.3 Purulence, Tissue inflammation | Abx Surgery 2 stage Rifampin (45)  | Yes                       |
| 2        | Joint pain, ↓ROM, Joint swelling | 3 (1)                                                                | 7.1 (2009)                                          | ESR 7, CRP 0.3                                         | Abx Surgery Debridement Rifampin (408)  | No                        |
| 3        | Joint pain, ↓ROM, Joint swelling, Erythema | 3 (1)                                                                | 8.4 (2010)                                          | Tissue inflammation                                  | Abx Surgery 1 stage Rifampin (580)    | Yes                       |
| 4        | Joint pain, ↓ROM            | 4 (1)                                                         | 6.5 (2012)                                          | ESR 5, CRP 0.1                                         | Abx Rifampin (196)                    | No                        |
| 5        | Joint pain, ↓ROM            | 4 (1)                                                         | 15 (2009)                                           | Purulence, Tissue inflammation                         | Abx Surgery Removal Rifampin (118)   | Yes                       |
| 6        | Joint pain, ↓ROM, Joint swelling, Erythema | 4 (1)                                                                | 16.7 (2011)                                         | ESR 30, CRP 2.1 Radiolucency Purulence, Tissue inflammation | Abx Surgery 2 stage Rifampin (162)   | Yes                       |
| 7        | Joint pain, ↓ROM            | 4 (1)                                                         | 4.6 (2011)                                          | Radiolucency, Component loosening Purulence, Tissue inflammation | Abx Surgery 2 Stage (83)             | Yes                       |
| 8        | Joint pain, ↓ROM            | 4 (1)                                                         | 7.4 (2009)                                          | ESR 10, CRP 0.4                                         | Abx Rifampin (1540)                   | Yes                       |
| 9        | Joint pain, ↓ROM            | 4 (1)                                                         | 54.4 (2012)                                         | ESR 11, CRP 1.2 Radiolucency                           | Abx                                    | LTFU                      |
| 10       | Joint pain, ↓ROM            | 4 (1)                                                         | 9 (2009)                                            |                                                      | Abx Surgery 1 Stage Rifampin (349)   | Yes                       |
| 11       | Joint pain, ↓ROM            | 4 (1)                                                         | 251 (2010)                                          |                                                      | Abx Surgery 1 Stage Rifampin (419)   | Yes                       |
| 12       | Joint pain, ↓ROM            | 4 (1)                                                         | 37 (2012)                                           | ESR 8, CRP 0.1                                         | Surgery 1 Stage                       | No                        |
| 13       | Joint pain                  | 5 (1)                                                         | 4.3 (2009)                                          | ESR 40, CRP 2.3 Component loosening Tissue inflammation | Abx Surgery 2 Stage Rifampin (649)   | No                        |
| 14       | Joint pain, ↓ROM, Joint swelling | 5 (1)                                                                | 55.4 (2010)                                         | ESR 26, CRP 0.2                                         | Abx Rifampin (232)                    | Yes                       |
| 15       | Joint pain, ↓ROM            | 5 (2)                                                         | 12.4 (2008)                                         | ESR 20, CRP 0.3 Purulence                              | Abx Surgery 2 Stage Rifampin (420)   | Yes                       |
| 16       | Joint pain, ↓ROM            | 5 (1)                                                         | 112 (2012)                                          | ESR 25, CRP 0.3 Tissue inflammation                    | Abx Surgery 2 Stage (170)            | Yes                       |
| 17       | Joint pain, ↓ROM, Warmth, Constitutional symptoms | 5 (1)                                                                | 2.8 (2011)                                          | ESR 37, CRP 4                                         | Abx Rifampin (770)                    | Yes                       |
PJIs, an initial nonsurgical antibiotic-only approach may find relevance for select patients with stable prostheses, particularly for those in whom surgical intervention may be contraindicated or declined.

Prior series have suggested the incorporation of rifampin into the antimicrobial management of *P. acnes* shoulder infections [18, 19]. Rifampin has been considered active against biofilms, the formation of which has been considered integral to the pathogenesis of *P. acnes* in prosthetic and other device-related infections [11, 31]. *Propionibacterium acnes* isolates associated with invasive prosthetic infections have been shown to have stronger biofilm formation capability than isolates from healthy skin [32]. Such biofilm-associated isolates have demonstrated increased antimicrobial resistance in vitro [33, 34]. Moreover, there has been in vivo animal data suggesting the efficacy of rifampin against *P. acnes* foreign-body-associated infections [35]. Recent Infectious Diseases Society of America guidelines recommend penicillin or ceftriaxone as first-line treatment for *P. acnes* PJIs with clindamycin or vancomycin as alternatives, and minocycline or doxycycline for suppressive therapy [3]. Adjunctive rifampin therapy is not included in these recommendations for *P. acnes* PIJ management. In this series, treatment outcomes were comparable with and without rifampin therapy. However, this drug was poorly tolerated and prematurely discontinued in 40% of cases. These findings suggest the role for rifampin in the management of *P. acnes* PJIs requires further study.

Recent studies have demonstrated the need for extended cultures to maximize recovery of pathogenic *P. acnes* isolates [27, 29]. In concordance with these findings, we observed a significant increase in the number of *P. acnes* shoulder PJIs subsequent to institution of an extended *P. acnes* culture protocol. Twenty-nine percent of *P. acnes* PJIs would have been missed otherwise, affirming the importance of these techniques [29].

In clinical settings, the majority of cases in our series occurred among males. These cases were primarily delayed or late presentations as observed in prior reports [17, 19, 22]. The male predominance for *P. acnes* shoulder PJIs correlates with the previously reported higher *P. acnes* bacterial burden for men compared with women at shoulder sites [10]. The indolent nature of this organism likely accounts for its predominantly late presentation. The majority of PJIs in this series presented with pain and functional limitation without fever or constitutional symptoms. Whereas the presence of joint pain in all cases may seem evident, such universal occurrence has not been reported in other series [17]. Previous reports have also suggested the occurrence of more apparent clinical symptoms with early PJIs [1]. However, we noted no difference in clinical presentation by time to presentation.

*Propionibacterium acnes* infections have often been characterized by the absence of elevated inflammatory markers [1]. However, inflammatory marker elevation has been noted in a significant proportion of cases in some series, occurring in over 70% of cases in 1 recent study [22, 36]. In our series, a notable proportion of PJIs occurred without elevated inflammatory markers, yet there was still evidence of inflammatory marker elevation in just under 50% of cases. Intraoperative purulence was similarly noted in just <50% of cases. The proportion of cases with histopathologic inflammation in our series (67%) was similar to previously reported observations [29, 37].

There have been reports of a shift in antimicrobial susceptibility patterns of *P. acnes* in the setting of the increasing use of
antimicrobial agents for acne vulgaris [25, 26, 38]. Yet, there have been reports of phylogenetic differences between acne-related \textit{P. acnes} isolates and deep device-related \textit{P. acnes} isolates, suggesting shifting acne-related resistance patterns may not reflect trends in susceptibility patterns for deep-seated, prosthetic-related infections [11]. However, there have also been reports of increased antimicrobial resistance for biofilm-associated \textit{P. acnes} isolates in vitro [33–35]. Furthermore, there have been recent reports of penicillin resistance even for \textit{P. acnes} isolates recovered from the shoulder joint [39]. In this series, all isolates tested were susceptible to vancomycin, rifampin, and β-lactams including penicillin. There was limited resistance noted to clindamycin. Despite widespread use of the tetracycline class for acne, minocycline MICs for this study population were all within the expected susceptibility range. The observed susceptibility patterns were similar to those of other recent series of \textit{P. acnes} shoulder isolates and suggest that in general, the broad antimicrobial susceptibility of \textit{P. acnes} isolates in deep shoulder PJIIs appears to be maintained [29, 39].

This study does carry the limitations of a primarily descriptive retrospective case series, without predefined diagnostic and therapeutic procedures, which could bias result interpretation. Assessment of clinical outcomes was also primarily qualitative. However, it is accepted that the primary goal of prosthetic joint replacement and PJI treatment is to improve quality of life by striving for a painless and functional joint, which were the criteria used to define a favorable study outcome [1, 6]. No gold standard exists for PJI diagnosis. However, we adapted previously applied criteria in our case definition [1, 3, 22, 29, 30]. On retrospective review, limited specimens were obtained for clinical evaluation. Furthermore, additional recent studies recovering \textit{P. acnes} from native joints or at the time of initial prosthesis placement, without clinical symptoms, raise concerns for the positive predictive value of shoulder-derived \textit{P. acnes} isolates [40,41]. Although additional studies are needed comparing the prognostic value of isolates from patients with and without clinical symptoms, we note our cases reflect patients postimplant, with active clinical manifestations previously identified as being associated with PJI regardless of organism. There have been recent reports considering shorter culture duration for optimal \textit{P. acnes} recovery [42]. However, clinical presentations were similar for patients with early or late \textit{P. acnes} culture detection. The shorter median follow-up time for the antibiotic-only group provided less time for observation of clinical outcomes. In addition, antibiotic-only cases were all diagnosed via joint arthrocentesis without operative intervention and were thus all classified as probable infections. However, we found no significant difference in the characteristics of these cases compared with those with more definitive operative and tissue findings for infection. Determination of which cases received an antibiotic-only approach could have been subject to selection bias. However, the rationale behind such case selection varied from patient preference and limited symptoms (ie, solid prosthesis with mild clinical symptoms) to severe comorbid disease (ie, nonoperative candidate), suggesting a wide clinical spectrum of host conditions selected for this approach, reducing the likelihood of this effect. All cases were treated with susceptible drugs.

**CONCLUSIONS**

Overall, this study contributes to better defining clinical characteristics of \textit{P. acnes} prosthetic shoulder infections. Furthermore, it is one of the few descriptions of the potential utility of nonsurgical management approaches for \textit{P. acnes} infections, which could include a trial of antibiotic therapy prior to surgical considerations. Future, larger studies prospectively evaluating alternative surgical and nonsurgical management approaches, oral versus parenteral therapy, optimal antibiotic duration, and appropriate patient selection will be needed for the further optimization of the clinical management of \textit{P acnes} infections.

**Acknowledgments**

We acknowledge Deborah Popoli and Qumars Roshanian (Johns Hopkins University School of Medicine, Department of Pathology) for assistance with data management.

**Financial support.** This work was supported by the Johns Hopkins University School of Medicine, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases.

**Potential conflicts of interest.** All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

**References**

1. Del Pozo JL, Patel R. Clinical practice. Infection associated with prosthetic joints. N Engl J Med 2009; 361:787–94.
2. Kurtz S, Ong K, Lau E, et al. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am 2007; 89:786–5.
3. Ormon DR, Berbari EF, Benend AR, et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2013; 56:e1–25.
4. Bohsali KI, Wirth MA, Rockwood CA Jr. Complications of total shoulder arthroplasty. J Bone Joint Surg Am 2006; 88:2279–92.
5. Darouiche RO. Treatment of infections associated with surgical implants. N Engl J Med 2004; 350:1422–9.
6. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med 2004; 351:1645–54.
7. Kurtz SM, Lau E, Watson H, et al. Economic burden of periprosthetic joint infection in the United States. J Arthroplasty 2012; 27:61.e1–5.
8. Grice EA, Kong HH, Conlan S, et al. Topographical and temporal diversity of the human skin microbiome. Science 2009; 324:1190–2.
9. Grice EA, Segre JA. The skin microbiome. Nat Rev Microbiol 2011; 9:244–53.
10. Patel A, Calfee BP, Plante M, et al. Propionibacterium acnes colonization of the human shoulder. J Shoulder Elbow Surg 2009; 18:897–902.
11. Achermann Y, Goldstein EL, Coenye T, Shirliff ME. Propionibacterium acnes: from commensal to opportunistic biofilm-associated pathogen. Clin Microbiol Rev 2014; 27:419–40.
12. Conen A, Watts LN, Merlo A, et al. Characteristics and treatment outcome of cerebrospinal fluid shunt-associated infections in adults: a retrospective analysis over an 11-year period. Clin Infect Dis 2008; 47:73–82.
13. Perry A, Lambert P. Propionibacterium acnes: infection beyond the skin. Expert Rev Anti Infect Ther 2011; 9:1149–56.
14. Achermann Y, Sahin F, Schwyzer HK, et al. Characteristics and outcome of 16 periprosthetic shoulder joint infections. Infection 2013; 41:613–20.
15. Dodson CC, Craig EV, Cordasco FA, et al. Propionibacterium acnes infection after shoulder arthroplasty: a diagnostic challenge. J Shoulder Elbow Surg 2010; 19:303–7.
16. Grosso MJ, Sabesan VJ, Ho JC, et al. Reinfection rates after 1-stage revision shoulder arthroplasty for patients with unexpected positive intraoperative cultures. J Shoulder Elbow Surg 2012; 21:754–8.

17. Kanafani ZA, Sexton DJ, Pien BC, et al. Postoperative joint infections due to Propionibacterium: a case-control study. Clin Infect Dis 2009; 49:1083–5.

18. Levy O, Iyer S, Atoun E, et al. Propionibacterium: an underestimated etiology in the pathogenesis of osteoarthritis? J Shoulder Elbow Surg 2013; 22:505–11.

19. Levy PY, Fenollar F, Stein A, et al. Propionibacterium postoperative shoulder arthritis: an emerging clinical entity. Clin Infect Dis 2008; 46:1884–6.

20. Singh JA, Sperling JW, Schleck C, et al. Periprosthetic infections after total shoulder arthroplasty: a 33-year perspective. J Shoulder Elbow Surg 2012; 21:1534–41.

21. Sulkowski MS, Abolnik IZ, Morris EI, Granger DL. Infectious arthritis due to Propionibacterium in a prosthetic joint. Clin Infect Dis 1994; 19:224–5.

22. Wang B, Toye B, Desjardins M, et al. A 7-year retrospective review from 2005 to 2011 of Propionibacterium shoulder infections in Ottawa, Ontario, Canada. Diagn Microbiol Infect Dis 2013; 75:195–9.

23. Zeller V, Ghorbani A, Strady C, et al. Propionibacterium: an agent of prosthetic joint infection and colonization. J Infect 2007; 55:119–24.

24. Denys GA, Farris RC, Swenson JM, Thornsberry C. Susceptibility of Propionibacterium acnes clinical isolates to 22 antimicrobial agents. Antimicrob Agents Chemother 1983; 23:335–7.

25. Eady EA, Gloor M, Leyden JJ. Propionibacterium acnes resistance: a worldwide problem. Dermatology 2003; 206:54–6.

26. Mendoza N, Hernandez PO, Tyring SK, et al. Antimicrobial susceptibility of Propionibacterium acnes isolates from acne patients in Colombia. Int J Dermatol 2013; 52:688–92.

27. Schafer F, Fich F, Lam M, et al. Prolonged bacterial culture to identify late periprosthetic joint infection: a promising strategy. Clin Infect Dis 2008; 47:1403–9.

28. Coste JS, Reig S, Trojani C, et al. The management of infection in arthroplasty for patients with unexpected positive intraoperative cultures. J Shoulder Elbow Surg 2011; 20:731–8.

29. Butler-Wu SM, Burns EM, Pottinger PS, et al. Optimization of periprosthetic culture for diagnosis of Propionibacterium acnes prosthetic joint infection. J Clin Microbiol Infect 2011; 49:2490–5.

30. Parvizi J, Zmistowski B, Berbari EF, et al. New definition for periprosthetic joint infection: from the Workgroup of the Musculoskeletal Infection Society. Clin Orthop Relat Res 2011; 469:2992–4.

31. Bayston R, Ashraf W, Barker-Davies R, et al. Biofilm formation by Propionibacterium acnes on biomaterials in vitro and in vivo: impact on diagnosis and treatment. J Biomed Mater Res A 2007; 81:705–9.

32. Holmberg A, Lood R, Morgelin M, et al. Biofilm formation by Propionibacterium acnes is a characteristic of invasive isolates. Clin Microbiol Infect 2009; 15:787–95.

33. Coenye T, Peeters E, Nelis HJ. Biofilm formation by Propionibacterium acnes is associated with increased resistance to antimicrobial agents and increased production of putative virulence factors. Res Microbiol 2007; 158:386–92.

34. Ramage G, Tunney MM, Patrick S, et al. Formation of Propionibacterium acnes biofilms on orthopaedic biomaterials and their susceptibility to antimicrobials. Biomaterials 2003; 24:3221–7.

35. Furustrand Ta, Corvec S, Betrisey B, et al. Role of rifampin against Propionibacterium acnes biofilm in vitro and in an experimental foreign-body infection model. Antimicrob Agents Chemother 2012; 56:1885–91.

36. Grosso MJ, Frangiamore SJ, Saleh A, et al. Poor utility of serum interleukin-6 levels to predict indolent periprosthetic shoulder infections. J Shoulder Elbow Surg 2014; 23:1227–81.

37. Grosso MJ, Frangiamore SJ, Ricchetti ET, et al. Sensitivity of frozen section histology for identifying Propionibacterium acnes infections in revision shoulder arthroplasty. J Bone Joint Surg Am 2014; 96:442–7.

38. Schafer F, Fich F, Lam M, et al. Antimicrobial susceptibility and genetic characteristics of Propionibacterium acnes isolated from patients with acute. Int J Dermatol 2013; 52:418–25.

39. Crane JK, Hohman DW, Nodzo SR, Duquin TR. Antimicrobial susceptibility of Propionibacterium acnes isolates from shoulder surgery. Antimicrob Agents Chemother 2013; 57:3424–6.

40. Hudek R, Sommer F, Kerwat M, et al. Propionibacterium acnes in shoulder surgery: true infection, contamination, or commensal of the deep tissue? J Shoulder Elbow Surg 2014; 23:1763–71.

41. Sethi PM, Sabetta JR, Stueck SJ, et al. Presence of Propionibacterium acnes in primary shoulder arthroscopy: results of aspiration and tissue cultures. J Shoulder Elbow Surg 2015; 24:796–803.

42. Shannon SK, Mandrekas J, Gustafson DR, et al. Anaerobic thioglycolate broth culture for recovery of Propionibacterium acnes from shoulder tissue and fluid specimens. J Clin Microbiol 2013; 51:731–2.